Regeneron Pharmaceuticals Inc (REGN) Director Sells $305,930.00 in Stock

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ REGN traded up $1.23 during trading on Wednesday, reaching $305.85. 733,270 shares of the company traded hands, compared to its average volume of 782,783. The firm has a market capitalization of $33.35 billion, a P/E ratio of 15.45, a PEG ratio of 1.44 and a beta of 1.08. Regeneron Pharmaceuticals Inc has a 12-month low of $291.10 and a 12-month high of $442.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.78 and a current ratio of 4.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.67 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $292,457,000. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.6% during the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the last quarter. Morgan Stanley increased its stake in shares of Regeneron Pharmaceuticals by 70.6% in the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock valued at $187,719,000 after purchasing an additional 192,236 shares in the last quarter. Parnassus Investments CA purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $65,699,000. Finally, AQR Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 65.9% in the 1st quarter. AQR Capital Management LLC now owns 383,857 shares of the biopharmaceutical company’s stock valued at $157,239,000 after purchasing an additional 152,469 shares in the last quarter. Institutional investors and hedge funds own 67.63% of the company’s stock.

A number of brokerages recently issued reports on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald restated a “hold” rating and issued a $441.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. Piper Jaffray Companies raised their target price on Regeneron Pharmaceuticals to $487.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. TheStreet upgraded Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Finally, Guggenheim lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $466.00 to $425.00 in a research note on Friday, February 22nd. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $404.88.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2019/05/15/regeneron-pharmaceuticals-inc-regn-director-sells-305930-00-in-stock.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How to Track your Portfolio in Google Finance

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply